Direxion Daily S&P Biotech Bull 3X ETF
LABU
19 hedge funds and large institutions have $29.8M invested in Direxion Daily S&P Biotech Bull 3X ETF in 2017 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 7 closing their positions.
29% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 7
12% more funds holding
Funds holding: 17 → 19 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.38% less ownership
Funds ownership: 0.72% → 0.35% (-0.38%)
30% less call options, than puts
Call options by funds: $36.5M | Put options by funds: $52M
38% less capital invested
Capital invested by funds: $48.3M → $29.8M (-$18.5M)
50% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
+$2.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$2.75M |
| 3 |
TSS
Two Sigma Securities
New York
|
+$1.12M |
| 4 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
+$605K |
| 5 |
Morgan Stanley
New York
|
+$597K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$11.5M |
| 2 |
Jane Street
New York
|
-$6.27M |
| 3 |
OPPM
Opus Point Partners Management
New York
|
-$1.37M |
| 4 |
ACM
Avalon Capital Management
Port Of Redwood City,
California
|
-$782K |
| 5 |
CG
Cutler Group
San Francisco,
California
|
-$664K |
LABU Hedge Fund Activity: Q4 2017 in Review
19 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Direxion Daily S&P Biotech Bull 3X ETF (LABU) for Q4 2017, worth a combined $29.8M — down 38% from $48.3M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new LABU positions and 7 closed out — a net gain of 2 holders — while 3 added to existing stakes and 6 trimmed.
The largest buyer was Bellevue Group, opening a new position worth an estimated $2.94M. The largest seller was Citigroup, cutting an estimated $11.5M.
- 19 institutional investors held Direxion Daily S&P Biotech Bull 3X ETF (LABU) as of Q4 2017, up from 17 in Q3 2017.
- Funds reported $29.8M of Direxion Daily S&P Biotech Bull 3X ETF stock for Q4 2017, down 38% quarter-over-quarter.
- 9 funds opened new Direxion Daily S&P Biotech Bull 3X ETF positions in Q4 2017 and 7 closed out, a net change of +2 holders.
- The largest Direxion Daily S&P Biotech Bull 3X ETF buyer in Q4 2017 was Bellevue Group, an estimated $2.94M added.
- The largest Direxion Daily S&P Biotech Bull 3X ETF seller in Q4 2017 was Citigroup, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2017.